Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab.

导出 LinkOut

翻译打印收藏纠错

第一作者： Agnish,Dey

第一单位： Clinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Boston, MA, United States.

作者： Agnish,Dey ^[1] ; Matthew,Austin ^[2] ; Harriet M,Kluger ^[2] ; Nataliya,Trunova ^[3] ; Helen,Mann ^[4] ; Norah,Shire ^[5] ; Claire,Morgan ^[6] ; Diansong,Zhou ^[1] ; Ganesh M,Mugundu ^[1]

作者单位： Clinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Boston, MA, United States. ^[1] School of Medicine, Yale University, New Haven, CT, United States. ^[2] Immuno-Oncology Franchise, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States. ^[3] Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. ^[4] Late Development Oncology, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States. ^[5] Patient Safety Oncology, AstraZeneca, Gaithersburg, MD, United States. ^[6]

关键词 biomarkers biostatistics clinical trials computational methods immunology immunotherapy lung cancer methodology and modeling

主题词人类(Humans);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);肺肿瘤(Lung Neoplasms);抗体, 单克隆(Antibodies, Monoclonal)

DOI 10.3389/fimmu.2022.1026964

PMID 36405729

发布时间 2022-11-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交